Innoviva, Inc. Net Worth 2010-2024 | INVA

Interactive chart of historical net worth (market cap) for Innoviva, Inc. (INVA) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Innoviva, Inc. net worth as of February 24, 2025 is $1.13B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharma $1.132B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly and Company (LLY) US $828.397B 67.21
Novo Nordisk A/S (NVO) DK $395.262B 26.77
Johnson & Johnson (JNJ) US $390.756B 16.25
AbbVie Inc. (ABBV) US $356.743B 19.97
Roche Holding AG (RHHBY) CH $264.174B 0.00
Merck & Co., Inc. (MRK) US $226.402B 11.72
Novartis AG (NVS) CH $223.511B 14.00
Pfizer Inc. (PFE) US $149.042B 8.46
Sanofi (SNY) $138.211B 13.09
Bayer Aktiengesellschaft (BAYRY) DE $22.635B 3.62